New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar

As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.

👉 Click here to access your FREE report now!

Bo Kruse Biography and Net Worth

CFO of Y-mAbs Therapeutics

Bo Kruse serves as Chief Financial Officer, Treasurer, and Secretary of the Company. Mr. Kruse has broad international finance experience, including knowledge of capital markets, accounting, and other financing activities. Prior to joining the Company, Mr. Kruse was the Chief Financial Officer of the Danish biotech company Azanta A/S from 2009 to 2015. Further, Mr. Kruse served as Genmab A/S’ Vice President and Chief Financial Officer from 2005 to 2008, and in a number of other finance positions, including Vice President and Chief Accounting Officer, from 2000 to 2005. During his eight-year tenure at Genmab, Mr. Kruse was directly involved in several financing rounds, including Genmab’s initial public offering. Mr. Kruse has a Master’s and Bachelor of Science in Commerce degree from Copenhagen Business School, Denmark.

What is Bo Kruse's net worth?: The estimated net worth of Bo Kruse is at least $2.22 million as of May 31st, 2024. Mr. Kruse owns 210,877 shares of Y-mAbs Therapeutics stock worth more than $2,222,644 as of November 21st. This net worth evaluation does not reflect any other assets that Mr. Kruse may own. Additionally, Mr. Kruse receives an annual salary of $685,020.00 as CFO at Y-mAbs Therapeutics. Learn More about Bo Kruse's net worth.
How old is Bo Kruse?: Mr. Kruse is currently 51 years old. There are 7 older executives and no younger executives at Y-mAbs Therapeutics. The oldest executive at Y-mAbs Therapeutics is Dr. Torben Lund-Hansen M.Sc., Ph.D., Senior VP & CTO, who is 73 years old. Learn More on Bo Kruse's age.
What is Bo Kruse's salary?: As the CFO of Y-mAbs Therapeutics, Inc., Mr. Kruse earns $685,020.00 per year. There are 2 executives that earn more than Mr. Kruse. The highest earning executive at Y-mAbs Therapeutics is Mr. Thomas Gad, Founder, Chief Business Officer & Vice Chairman, who commands a salary of $1,050,000.00 per year. Learn More on Bo Kruse's salary.
How do I contact Bo Kruse?: The corporate mailing address for Mr. Kruse and other Y-mAbs Therapeutics executives is 230 Park Avenue Suite 3350, NEW YORK NY, 10169. Y-mAbs Therapeutics can also be reached via phone at (646) 885-8505 and via email at [email protected]. Learn More on Bo Kruse's contact information.
Has Bo Kruse been buying or selling shares of Y-mAbs Therapeutics?: Bo Kruse has not been actively trading shares of Y-mAbs Therapeutics within the last three months. Most recently, Bo Kruse sold 31,371 shares of the business's stock in a transaction on Friday, May 31st. The shares were sold at an average price of $12.07, for a transaction totalling $378,647.97. Following the completion of the sale, the chief financial officer now directly owns 210,877 shares of the company's stock, valued at $2,545,285.39. Learn More on Bo Kruse's trading history.
Who are Y-mAbs Therapeutics' active insiders?: Y-mAbs Therapeutics' insider roster includes Thomas Gad (Insider), Jorris Jan Wilms (Sr. VP & COO ), Bo Kruse (CFO), Vignesh Rajah (CMO), and Johan Wedell-Wedellsborg (Director). Learn More on Y-mAbs Therapeutics' active insiders.
Are insiders buying or selling shares of Y-mAbs Therapeutics?: During the last twelve months, Y-mAbs Therapeutics insiders bought shares 4 times. They purchased a total of 223,399 shares worth more than $1,413,938.86. During the last twelve months, insiders at the sold shares 11 times. They sold a total of 301,155 shares worth more than $3,229,807.80. The most recent insider tranaction occured on September, 16th when insider Thomas Gad sold 30,000 shares worth more than $389,100.00. Insiders at Y-mAbs Therapeutics own 22.5% of the company. Learn More about insider trades at Y-mAbs Therapeutics.
Information on this page was last updated on 9/16/2024.

Bo Kruse Insider Trading History at Y-mAbs Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/31/2024	Sell	31,371	$12.07	$378,647.97	210,877
2/22/2022	Sell	4,000	$7.85	$31,400.00
2/4/2022	Sell	4,000	$7.97	$31,880.00
1/24/2022	Sell	4,000	$9.84	$39,360.00
1/4/2022	Sell	4,000	$17.12	$68,480.00
12/22/2021	Sell	4,000	$16.36	$65,440.00
12/6/2021	Sell	4,000	$16.35	$65,400.00
11/22/2021	Sell	4,000	$18.09	$72,360.00
10/22/2021	Sell	4,000	$25.94	$103,760.00
10/4/2021	Sell	4,000	$28.78	$115,120.00
9/22/2021	Sell	4,000	$30.82	$123,280.00
9/7/2021	Sell	4,000	$32.03	$128,120.00	225,077
8/23/2021	Sell	4,000	$28.60	$114,400.00
8/4/2021	Sell	4,000	$33.72	$134,880.00
7/22/2021	Sell	4,000	$34.50	$138,000.00
7/22/2021	Sell	4,000	$34.50	$138,000.00
7/6/2021	Sell	4,000	$34.15	$136,600.00
6/22/2021	Sell	4,000	$36.17	$144,680.00	245,077
6/4/2021	Sell	4,000	$33.48	$133,920.00	249,077
5/24/2021	Sell	4,000	$35.61	$142,440.00	253,077
5/13/2020	Sell	14,724	$37.86	$557,450.64	285,276

Bo Kruse Buying and Selling Activity at Y-mAbs Therapeutics

Y-mAbs Therapeutics Company Overview

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

Today's Range

Now: $10.54

$10.34

$11.11

50 Day Range

MA: $13.82

$10.54

$15.69

2 Week Range

Now: $10.54

$5.17

$20.90

Volume

236,780 shs

Average Volume

280,054 shs

Market Capitalization

$472.09 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.68

Download Our Tesla Ebook For Free

From DTI | Ad

Like many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.

To claim your copy free of charge simply follow this link.

Bo Kruse Biography and Net Worth

What is Bo Kruse's net worth?

How old is Bo Kruse?

What is Bo Kruse's salary?

How do I contact Bo Kruse?

Has Bo Kruse been buying or selling shares of Y-mAbs Therapeutics?

Who are Y-mAbs Therapeutics' active insiders?

Are insiders buying or selling shares of Y-mAbs Therapeutics?